BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24367252)

  • 21. A recombinant beta-1,3-glucanosyltransferase homolog of Coccidioides posadasii protects mice against coccidioidomycosis.
    Delgado N; Xue J; Yu JJ; Hung CY; Cole GT
    Infect Immun; 2003 Jun; 71(6):3010-9. PubMed ID: 12761077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.
    Tarcha EJ; Basrur V; Hung CY; Gardner MJ; Cole GT
    Infect Immun; 2006 Jan; 74(1):516-27. PubMed ID: 16369008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccines against Coccidioides.
    Yoon HJ; Clemons KV
    Korean J Intern Med; 2013 Jul; 28(4):403-7. PubMed ID: 23864796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis.
    Hurtgen BJ; Hung CY; Ostroff GR; Levitz SM; Cole GT
    Infect Immun; 2012 Nov; 80(11):3960-74. PubMed ID: 22949556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole glucan particles as a vaccine against systemic coccidioidomycosis.
    Clemons KV; Antonysamy MA; Danielson ME; Michel KS; Martinez M; Chen V; Stevens DA
    J Med Microbiol; 2015 Oct; 64(10):1237-1243. PubMed ID: 26297127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant urease and urease DNA of Coccidioides immitis elicit an immunoprotective response against coccidioidomycosis in mice.
    Li K; Yu JJ; Hung CY; Lehmann PF; Cole GT
    Infect Immun; 2001 May; 69(5):2878-87. PubMed ID: 11292702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deficient resistance to Coccidioides immitis following intravenous vaccination. II. Evidence against an immune tolerance mechanism.
    Scalarone GM; Levine HB
    Sabouraudia; 1971 Jul; 9(2):90-6. PubMed ID: 4939207
    [No Abstract]   [Full Text] [Related]  

  • 28. Deficient resistance to Coccidioides immitis following intravenous vaccination. I. Distribution of spherules after intravenous and intramuscular doses.
    Scalarone GM; Levine HB
    Sabouraudia; 1971 Jul; 9(2):81-9. PubMed ID: 5111562
    [No Abstract]   [Full Text] [Related]  

  • 29. Flow Cytometric Analysis of Protective T-Cell Response Against Pulmonary Coccidioides Infection.
    Hung CY; Wozniak KL; Cole GT
    Methods Mol Biol; 2016; 1403():551-66. PubMed ID: 27076153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deficient resistance to Coccidioides immitis following intravenous vaccination. 3. Humoral and cellular responses to intravenous and intramuscular doses.
    Levine HB; Scalarone GM
    Sabouraudia; 1971 Jul; 9(2):97-108. PubMed ID: 5111563
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group.
    Pappagianis D
    Am Rev Respir Dis; 1993 Sep; 148(3):656-60. PubMed ID: 8368636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccinated C57BL/6 mice develop protective and memory T cell responses to Coccidioides posadasii infection in the absence of interleukin-10.
    Hung CY; Castro-Lopez N; Cole GT
    Infect Immun; 2014 Feb; 82(2):903-13. PubMed ID: 24478103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coccidioides immitis vaccine: potential of an alkali-soluble, water-soluble cell wall antigen.
    Lecara G; Cox RA; Simpson RB
    Infect Immun; 1983 Jan; 39(1):473-5. PubMed ID: 6822433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-type lectin receptors differentially induce th17 cells and vaccine immunity to the endemic mycosis of North America.
    Wang H; LeBert V; Hung CY; Galles K; Saijo S; Lin X; Cole GT; Klein BS; Wüthrich M
    J Immunol; 2014 Feb; 192(3):1107-1119. PubMed ID: 24391211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic vaccination against Coccidioides immitis: comparison of vaccine efficacy of recombinant antigen 2 and antigen 2 cDNA.
    Jiang C; Magee DM; Quitugua TN; Cox RA
    Infect Immun; 1999 Feb; 67(2):630-5. PubMed ID: 9916069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and cellular mechanisms of protective immunity to coccidioidomycosis.
    Kirkland TN; Raz E; Datta SK
    Vaccine; 2006 Jan; 24(4):495-500. PubMed ID: 16181709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17).
    Hung CY; Gonzalez A; Wüthrich M; Klein BS; Cole GT
    Infect Immun; 2011 Nov; 79(11):4511-22. PubMed ID: 21859851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maize-Produced Ag2 as a Subunit Vaccine for Valley Fever.
    Hayden CA; Hung CY; Zhang H; Negron A; Esquerra R; Ostroff G; Abraham A; Lopez AG; Gonzales JE; Howard JA
    J Infect Dis; 2019 Jul; 220(4):615-623. PubMed ID: 31184702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of B cells in vaccine-induced immunity against coccidioidomycosis.
    Magee DM; Friedberg RL; Woitaske MD; Johnston SA; Cox RA
    Infect Immun; 2005 Oct; 73(10):7011-3. PubMed ID: 16177382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attributes of deficient immunity in mice receiving Coccidioides immitis Spherule vaccine by the intravenous route.
    Scalarone GM; Levine HB
    Sabouraudia; 1969 Oct; 7(3):169-77. PubMed ID: 5385153
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.